Faron Pharmaceuticals H1: Turbulent times behind, promising times ahead - Redeye

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report. With upcoming BEXMAB read-outs and a planned pivotal study ahead and a potential license deal on the horizon, we see promising times ahead for the company. Following the company’s recent clinical progression, positive FDA feedback and a granted Fast Track Designation, we increase our base case valuation to EUR2.8 (2) per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/1035373/faron-pharmaceuticals-h1-turbulent-times-behind-promising-times-ahead?utm_source=finwire&utm_medium=RSS